Halozyme Therapeutics Inc. Reaches New 12-Month High at $16.45 (HALO)
Halozyme Therapeutics (NASDAQ:HALO)’s share price reached a new 52-week high during trading hours on Thursday, AnalystRatingsNetwork reports. The company traded as high as $16.45 and last traded at $16.21, with a volume of 1,039,322 shares traded. The stock had previously closed at $15.76.
HALO has been the subject of a number of recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Halozyme Therapeutics from $13.00 to $17.00 in a research note to investors on Monday, November 11th. Separately, analysts at Barclays raised their price target on shares of Halozyme Therapeutics from $8.00 to $12.00 in a research note to investors on Monday, November 11th. They now have an “equal weight” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Halozyme Therapeutics from $8.00 to $14.00 in a research note to investors on Monday, November 11th. They now have a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $10.71.
Halozyme Therapeutics has a 52 week low of $5.03 and a 52 week high of $16.36. The stock has a 50-day moving average of $14.48 and a 200-day moving average of $10.62. The company’s market cap is $1.821 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.02. The company had revenue of $16.00 million for the quarter, compared to the consensus estimate of $14.62 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was up 200.2% on a year-over-year basis. On average, analysts predict that Halozyme Therapeutics will post $-0.71 earnings per share for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.